MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17562848261452511

Медицинская библиотека · Therapeutic advances in gastroenterology · 2026

Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.

Alonso-Abreu Inmaculada, Ramos Laura, Hernandez-Camba Alejandro, Yagüe-Caballero Carmen, Vicente Lidón Raquel, Taxonera Carlos, García-Brenes Miguel A, Gisbert Javier P, Chaparro Maria, Madero Velázquez Lucia, Carrillo-Palau Marta, Arranz Laura, Castro Senosiain Beatriz, García de la Filia Molina Irene, Rojas-Feria María, López Romero-Salazar Francisco, Bastón-Rey Iria, Sánchez-Azofra María, Riestra Sabino, Pérez-Galindo Pablo, Ortega Moya Silvia Patricia, Brunet-Mas Eduard, Segura Patricia Sanz, Caballero Mateos Antonio M, Calafat Margalida, Botella Mateu Belén, Manceñido Marcos Noemí, Rodríguez-Lago Iago, Ferrer Cristina Suarez, Gutiérrez Ana

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Inflammatory bowel disease (IBD) and celiac disease (CeD) are immune-mediated digestive disorders with shared genetic, immunological, and environmental risk factors.

OBJECTIVES

This study aimed to assess whether the coexistence of CeD and IBD is associated with a differential IBD disease course.

DESIGN

Multicenter case-control study.

METHODS

This study included patients with both CeD and IBD, and controls with IBD alone in a 1:2 ratio, matched by sex, IBD type, and year of diagnosis. CeD was diagnosed based on a Marsh score >1. Data on IBD phenotype and treatment, mortality and neoplasm development were collected from medical records.

RESULTS

The study included 66 celiac-IBD patients (30 ulcerative colitis, 6 indeterminate colitis, 30 Crohn's disease; mean age 30 ± 14 years) and 132 non-celiac-IBD patients (68 ulcerative colitis, 4 indeterminate colitis, 60 Crohn's disease; mean age 32 ± 14 years). Among patients with CeD, Marsh type 3 was the most frequently observed lesion. No significant differences were observed between celiac and non-celiac-IBD patients in terms of IBD extension, extraintestinal manifestations, or coexisting autoimmune diseases. Similarly, no differences were found in outcomes including perianal disease, use of mesalamine, immunomodulators, biologics, need for surgery, or development of neoplasms. No deaths occurred in either group.

CONCLUSION

In this large multicenter cohort, the concurrent diagnosis of CeD and patients with IBD was not associated with a different IBD phenotype or worse outcomes compared to non-celiac-IBD patients. The coexistence of CeD does not appear to alter the natural history of IBD.

Для цитирования: Alonso-Abreu Inmaculada, Ramos Laura, Hernandez-Camba Alejandro, Yagüe-Caballero Carmen, Vicente Lidón Raquel, Taxonera Carlos, García-Brenes Miguel A, Gisbert Javier P, Chaparro Maria, Madero Velázquez Lucia, Carrillo-Palau Marta, Arranz Laura, Castro Senosiain Beatriz, García de la Filia Molina Irene, Rojas-Feria María, López Romero-Salazar Francisco, Bastón-Rey Iria, Sánchez-Azofra María, Riestra Sabino, Pérez-Galindo Pablo, Ortega Moya Silvia Patricia, Brunet-Mas Eduard, Segura Patricia Sanz, Caballero Mateos Antonio M, Calafat Margalida, Botella Mateu Belén, Manceñido Marcos Noemí, Rodríguez-Lago Iago, Ferrer Cristina Suarez, Gutiérrez Ana. Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.. Therapeutic advances in gastroenterology. 2026. DOI: 10.1177/17562848261452511.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.